# US 2019/0240151 A1 · Vasoconstriction compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240151 A1
- Document ID: US20190240151A1
- Status: Published application
- Kind: A1
- Application number: 16/179,261
- Filed: 2018-11-02
- Published: 2019-08-08
- Earliest claimed: 2008-08-01
- Assignees: Eye Therapies LLC
- Applicants: Eye Therapies LLC
- Inventors: Gerald HORN
- Web page: https://patentgrep.com/patent/US20190240151A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 23/02: Local anaesthetics
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A method of reducing ocular redness in a subject in need thereof comprising administering to the ocular surface a single drop of an ophthalmic formulation comprising brimonidine as the sole active ingredient at a concentration less than 0.07%, wherein the ophthalmic formulation is administered no more than 4 time a day.

### Claim 15 (depends on 14)

The method of claim 14, wherein the brimonidine is at a concentration less than 0.05%.

### Claim 16 (depends on 14)

The method of claim 14, wherein the brimonidine is at a concentration less than 0.03%.

### Claim 17 (depends on 14)

The method of claim 14, wherein the brimonidine is at a concentration of about between 0.005% to 0.05%.

### Claim 18 (depends on 14)

The method of claim 14, wherein the brimonidine is at a concentration of about between 0.001% to 0.05%.

### Claim 19 (depends on 14)

The method of claim 14, wherein the brimonidine is at a concentration of about between 0.001% to 0.025%.

### Claim 20 (depends on 14)

The method of claim 14, wherein the brimonidine is at a concentration of about 0.025%.

### Claim 21 (depends on 14)

The method of claim 14, wherein the ophthalmic formulation comprises an electrolyte or preservative.

### Claim 22 (depends on 14)

The method of claim 14, wherein the ophthalmic formulation comprises one or more of sodium chloride, magnesium ions, mannitol, carboxymethyl cellulose hyaluronic acid, glycerin, potassium chloride, calcium chloride, benzalkonium chloride, or water.

### Claim 23 (depends on 14)

The method of claim 14, wherein the ophthalmic formulation comprises glycerin, potassium chloride, calcium chloride, benzalkonium chloride, and water

### Claim 24 (depends on 14)

The method of claim 14, wherein the ophthalmic formulation comprises a buffering agent.

### Claim 25 (depends on 24)

The method of claim 24, wherein the buffering agent is citrate.

### Claim 26 (depends on 14)

The method of claim 14, wherein the ophthalmic formulation has a pH of about between 5.0-7.8.

### Claim 27 (depends on 14)

The method of claim 14, wherein the drop is no more than 50 μL.

### Claim 28

A method of reducing ocular redness in a subject in need thereof comprising administering to the ocular surface a single drop of an ophthalmic formulation comprising brimonidine as the sole active ingredient at a concentration less than 0.07%, wherein said administration does not result in ocular ischemia.

### Claim 29 (depends on 28)

The method of claim 28, wherein the brimonidine is at a concentration less than 0.05%.

### Claim 30 (depends on 28)

The method of claim 28, wherein the brimonidine is at a concentration less than 0.03%.

### Claim 31 (depends on 28)

The method of claim 28, wherein the brimonidine is at a concentration of about between 0.005% to 0.05%.

### Claim 32 (depends on 28)

The method of claim 28, wherein the brimonidine is at a concentration of about between 0.001% to 0.05%.

### Claim 33 (depends on 28)

The method of claim 28, wherein the brimonidine is at a concentration of about between 0.001% to 0.025%.

### Claim 34 (depends on 28)

The method of claim 28, wherein the brimonidine is at a concentration of about 0.025%.

### Claim 35 (depends on 28)

The method of claim 28, wherein the ophthalmic formulation is administered no more than 4 time a day.

### Claim 36 (depends on 28)

The method of claim 28, wherein the ophthalmic formulation comprises an electrolyte or preservative.

### Claim 37 (depends on 28)

The method of claim 28, wherein the ophthalmic formulation comprises one or more of sodium chloride, magnesium ions, mannitol, carboxymethyl cellulose hyaluronic acid, glycerin, potassium chloride, calcium chloride, benzalkonium chloride, or water.

### Claim 38 (depends on 28)

The method of claim 28, wherein the ophthalmic formulation comprises glycerin, potassium chloride, calcium chloride, benzalkonium chloride, and water

### Claim 39 (depends on 28)

The method of claim 28, wherein the ophthalmic formulation comprises a buffering agent.

### Claim 40 (depends on 39)

The method of claim 39, wherein the buffering agent is citrate.

### Claim 41 (depends on 28)

The method of claim 28, wherein the ophthalmic formulation has a pH of about between 5.0-7.8.

### Claim 42 (depends on 28)

The method of claim 28, wherein the drop is no more than 50 μL.

### Claim 43

A method of reducing ocular redness in a subject in need thereof comprising administering to the ocular surface a single drop of an ophthalmic formulation comprising as the sole active ingredient at a concentration less than 0.07% wherein said administration is not within 24 hrs. prior to or after the subject has had an ocular surgery.

### Claim 44 (depends on 43)

The method of claim 43, wherein the brimonidine is at a concentration less than 0.05%.

### Claim 45 (depends on 43)

The method of claim 43, wherein the brimonidine is at a concentration less than 0.03%.

### Claim 46 (depends on 43)

The method of claim 43, wherein the brimonidine is at a concentration of about between 0.005% to 0.05%.

### Claim 47 (depends on 43)

The method of claim 43, wherein the brimonidine is at a concentration of about between 0.001% to 0.05%.

### Claim 48 (depends on 43)

The method of claim 43, wherein the brimonidine is at a concentration of about between 0.001% to 0.025%.

### Claim 49 (depends on 43)

The method of claim 43, wherein the brimonidine is at a concentration of about 0.025%.

### Claim 50 (depends on 43)

The method of claim 43, wherein the ophthalmic formulation is administered no more than 4 time a day.

### Claim 51 (depends on 43)

The method of claim 43, wherein the ophthalmic formulation comprises an electrolyte or preservative.

### Claim 52 (depends on 43)

The method of claim 43, wherein the ophthalmic formulation comprises one or more of sodium chloride, magnesium ions, mannitol, carboxymethyl cellulose hyaluronic acid, glycerin, potassium chloride, calcium chloride, benzalkonium chloride, or water.

### Claim 53 (depends on 43)

The method of claim 43, wherein the ophthalmic formulation comprises a buffering agent.

### Claim 54 (depends on 53)

The method of claim 53, wherein the buffering agent is citrate.

### Claim 55 (depends on 43)

The method of claim 43, wherein the ophthalmic formulation has a pH of about between 5.0-7.8.

### Claim 56 (depends on 43)

The method of claim 43, wherein the drop is no more than 50 μL.

### Claim 57

A formulation comprising 0.025% brimonidine as the sole active ingredient, glycerin, potassium chloride, calcium chloride dehydrate, benzalkonium chloride, water wherein said formulation is suitable for administration to the ocular surface.

### Claim 58 (depends on 57)

The formulation of claim 57, wherein administration does not result in ocular ischemia.

### Claim 59 (depends on 57)

The formulation of claim 57, wherein the formulation has a pH of about between 5.0-7.8.

### Claim 60

A formulation comprising 0.09% or less brimonidine as the sole active ingredient and one or more of a surfactant, electrolyte, or preservative.

### Claim 61 (depends on 60)

A formulations of claim 60, wherein the formulation comprises 0.05% or less brimonidine.

### Claim 62 (depends on 60)

A formulations of claim 60, wherein the formulation comprises 0.025% or less brimonidine

### Claim 63 (depends on 60)

The formulation of claim 60, wherein the formulation comprises one or more of sodium chloride, magnesium ions, mannitol, carboxymethyl cellulose hyaluronic acid, glycerin, potassium chloride, calcium chloride, benzalkonium chloride, or water wherein said formulation is suitable for administration to the ocular surface.

### Claim 64 (depends on 60)

The formulation of claim 60, wherein the formulation comprises a buffering agent.

### Claim 65 (depends on 60)

The formulation of claim 60, wherein the buffering agent is citrate.

### Claim 66 (depends on 60)

The formulation of claim 60, wherein the formulation has a pH of about between 5.0-7.8.
